A clinical trial in glioblastoma patients of HER2-targeted CAR-NK cells generated by lentiviral transduction of the NK-92 cell line (CAR2BRAIN [35] NCT03383978) is scheduled for completion in 2022. This evidence concerns the gene ERBB2 and glioblastoma.